Fogh J. Human tumor cells in vitro. New York: Plenum Press; 1975.
Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 77210034
Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321
Morimoto H, et al. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin- mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J. Immunol. 147: 2609-2616, 1991. PubMed: 1918981
Zhang X, et al. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res. 57: 3751-3758, 1997. PubMed: 9288783
Clinton GM, et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc. Natl. Acad. Sci. USA 93: 316-320, 1996. PubMed: 8552629
Zhang X, Smith CD. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Mol. Pharmacol. 49: 288-294, 1996. PubMed: 8632761
Wiechen K, et al. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells. Br. J. Cancer 81: 790-795, 1999. PubMed: 10555747
Yu D, et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53: 891-898, 1993. PubMed: 8094034
Karlan BY, et al. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gyn. Onc. 53: 70-77, 1994. PubMed: 7909787
|